Entity

Time filter

Source Type

Berlin, Germany

Scherbakov N.,Charite - Medical University of Berlin | Scherbakov N.,Berlin Partner | Sandek A.,Charite - Medical University of Berlin | Doehner W.,Charite - Medical University of Berlin
Journal of the American Medical Directors Association | Year: 2015

Sarcopenia is characterized by muscle wasting and is primarily a disease of the elderly. A stroke-specific sarcopenia has been described recently. Stroke-related sarcopenia has a number of features that distinguish it from the age-related sarcopenia. The disability from stroke depends on the brain lesion leading to impairment of the efferent neuronal pathways. However, the alterations of structural and functional muscle capacity are secondary and depend rather on complex pathophysiological reactions including imbalanced efferent neurovegetative control, systemic and local metabolic imbalance, feeding difficulties, and inflammation. Muscle structural changes start to develop within hours after stroke, followed by rapid reduction of muscle mass. The pathophysiological mechanisms leading to the muscle mass decline are still not understood in details. This review provides insights into the specific features of the stroke-related sarcopenia. Recent research achievements in this area and clinical implications will be discussed. © 2015.


Wilck N.,Charite - Medical University of Berlin | Wilck N.,Max Delbruck Center for Molecular Medicine | Ludwig A.,Charite - Medical University of Berlin | Ludwig A.,Berlin Partner
Antioxidants and Redox Signaling | Year: 2014

Significance: Atherosclerosis is a vascular disease of worldwide significance with fatal complications such as myocardial infarction, stroke, and peripheral artery disease. Atherosclerosis is recognized as a chronic inflammatory disease leading to arterial plaque formation and vessel narrowing in different vascular beds. Besides the strong inflammatory nature of atherosclerosis, it is also characterized by proliferation, apoptosis, and enhanced oxidative stress. The ubiquitin-proteasome system (UPS) is the major intracellular degradation system in eukaryotic cells. Besides its essential role in the degradation of dysfunctional and oxidatively damaged proteins, it is involved in many processes that influence disease progression in atherosclerosis. Hence, it is logical to ask whether targeting the proteasome is a reasonable and feasible option for the treatment of atherosclerosis. Recent Advances: Several lines of evidence suggest stage-specific dysfunction of the UPS in atherogenesis. Regulation of key processes by the proteasome in atherosclerosis, as well as the modulation of these processes by proteasome inhibitors in vascular cells, is outlined in this review. The treatment of atherosclerotic animal models with proteasome inhibitors yielded partly opposing results, the potentially underlying reasons of which are discussed here. Critical Issues and Future Directions: Targeting UPS function in atherosclerosis is a promising but challenging option. Limitations of current proteasome inhibitors, dose dependency, and the cell specificity of effects, as well as the potential of future therapeutics are discussed. A stage-specific in-depth exploration of UPS function in atherosclerosis in the future will help identify targets and windows for beneficial intervention. © 2014, Mary Ann Liebert, Inc.


Schmidt S.,SNSB Zoologische Staatssammlung | Schmid-Egger C.,Berlin Partner | Moriniere J.,SNSB Zoologische Staatssammlung | Haszprunar G.,SNSB Zoologische Staatssammlung | Hebert P.D.N.,University of Guelph
Molecular Ecology Resources | Year: 2015

This study presents DNA barcode records for 4118 specimens representing 561 species of bees belonging to the six families of Apoidea (Andrenidae, Apidae, Colletidae, Halictidae, Megachilidae and Melittidae) found in Central Europe. These records provide fully compliant barcode sequences for 503 of the 571 bee species in the German fauna and partial sequences for 43 more. The barcode results are largely congruent with traditional taxonomy as only five closely allied pairs of species could not be discriminated by barcodes. As well, 90% of the species possessed sufficiently deep sequence divergence to be assigned to a different Barcode Index Number (BIN). In fact, 56 species (11%) were assigned to two or more BINs reflecting the high levels of intraspecific divergence among their component specimens. Fifty other species (9.7%) shared the same Barcode Index Number with one or more species, but most of these species belonged to a distinct barcode cluster within a particular BIN. The barcode data contributed to clarifying the status of nearly half the examined taxonomically problematic species of bees in the German fauna. Based on these results, the role of DNA barcoding as a tool for current and future taxonomic work is discussed. © 2015 The Authors.


Grant
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: INNOSUP | Award Amount: 78.75K | Year: 2014

Berlin Partner fr Wirtschaft und Technologie GmbH (BP) and ZukunftsAgentur Brandenburg GmbH (ZAB), the two economic and technology development agencies of Berlin and Brandenburg, both partners in the Berlin-Brandenburg Enterprise Europe Network consortium, are going to offer innovation management consultancy to SMEs with high potential for innovation, internationalization and growth. The new service will allow the agencies to broaden their service portfolio to SMEs and to support existing programmes for research and innovation. While the latter usually concentrate on technologies and other outputs, InnoManage BB will focus on internal management processes and capacities in the SME in order for them to successfully innovate. Target groups of InnoManage BB are a) companies which have successfully applied for funding in the SME instrument of H2020, and b) other SME in Berlin and Brandenburg which show the potential for innovation, internationalization and growth. As both BP and ZAB have been responsible for realizing the innovation strategies of their respective federal states since more than ten years, both agencies are fully familiar with the scope and challenges facing innovation-orientated companies. BP aims to consult 11 SME in 2014, ZAB 7.


Grant
Agency: Cordis | Branch: H2020 | Program: SGA-CSA | Phase: INNOVATION | Award Amount: 279.60K | Year: 2015

Berlin Partner fr Wirtschaft und Technologie GmbH (BP) and ZAB ZukunftsAgentur Brandenburg (ZAB), the two economic and technology development agencies of Berlin and Brandenburg, both partners in the Berlin-Brandenburg Enterprise Europe Network consortium, are going to offer innovation management consultancy to SMEs with high potential for innovation, internationalization and growth. This newly developed service will allow the agencies to broaden their service portfolio to SMEs und to support existing programmes for research and innovation. While the latter usually concentrate on technologies and other outputs, InnoManage BB 2015-2016 will focus an internal management processes and capacities in the SME in order for them to successfully innovate. Target groups of InnoManage BB 2015-2016 are a) companies which have successfully applied for funding under the SME Instrument of H2020, and b) other SMEs in Berlin and Brandenburg which show the potential for innovation, internationalization and growth. As both BP and ZAB have been responsible for realizing the innovation strategies of their respective federal states since more than ten years, both agencies are fully familiar with the scope and challenges fading innovation-orientated companies. Within the frame of this project, BP and ZAB intend to carry out 71 service packages in total, BP will take over 40 service packages, ZAB 31 service packages.

Discover hidden collaborations